GSK’s Dovato hits endpoints in late-stage study
In a Phase III study the drug combo was as effective in controlling HIV-1 as a Vemlidy combo.
Read More
Tag: lamivudine
ViiV secures EU nod for HIV therapy Dovato
Availability of the two-drug regimen is considered a significant development for people with the condition
Read More
GSK’s HIV drug Dovato gets FDA approval
It marks the first two-drug complete regimen for HIV-infected patients.
Read More
US filing for ViiV’s two-drug, single pill HIV treatment
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.
Read More
ViiV submits two-drug regimen for HIV in Europe
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
Read More
ViiV unveils positive data for two-drug HIV regimens
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
Read More
ViiV’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
Read More
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
